Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
HAMPTON, N.J., March 03, 2016 -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony Marucci, Co-founder, President and Chief Executive Officer, will provide a corporate overview at the Cowen and Company 36th Annual Health Care Conference on Tuesday, March 8, 2016 at 10:00 a.m. EST in Boston.
The live webcast of the presentation will be available on the “Events & Presentations” page of the “Investors & Media” section of the Celldex website. A replay of the presentation will be archived for seven days following the event.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact: Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
